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EFFECTS OF GLUCOCORTICOIDS ON CHONDROCYTES AND CARTILAGE 
 
 
WALLACE CHELSEY 
 
 
ABSTRACT 
Objective: Osteoarthritis (OA) is a leading cause of disability worldwide. This disease is 
characterized by the inflammation and degradation of the cartilage and surrounding tissue 
in a joint. The disease manifests as either a result of years of wear and tear or after a joint 
injury. Post-traumatic osteoarthritis, as this latter case is named, is frequently studied 
since the exact trigger of the disease is known. In addition to several changes within the 
joint space, a significant alteration is the degradation of cartilage caused primarily by the 
release of inflammatory cytokines including interleukin-1 and 6 and tumor necrosis factor 
α. One current pharmacological treatment for the pain caused by OA is an intra-articular 
injection of glucocorticoids such as dexamethasone. As this is a common treatment, the 
goal of this research was to determine if, at the cellular level, this treatment impacts cell 
viability in the presence of pro-inflammatory cytokines. Another goal was to investigate 
how such treatment affects the progression of cartilage degradation caused by cytokines. 
OA results in the loss of the key extracellular matrix molecule, aggrecan, which contains 
negatively charged glycosaminoglycan (GAG) chains. Measurement of the amount of 
GAGs lost is an early indicator of cartilage degradation. In addition, biosynthesis of GAG 
chains can be measured to estimate the overall metabolic health of the cells. We 
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hypothesized that dexamethasone blunts the harmful effects of proinflammatory 
cytokines and improves GAG biosynthesis and chondrocyte viability.  
Methods: Cylindrical cartilage explants were collected from bovine knee joints and 
trimmed to a uniform 3 millimeters in diameter and 1 millimeter thick. Each treatment 
group consisted of n=6 explants from the same knee joint. In one set of experiments, 
these explants were subjected to two different doses of interleukin-1α (1 ng/mL and 10 
ng/mL) with and without dexamethasone at 100 nM. In another set of experiments, 
explants were subjected to both interleukin-1α and tumor necrosis factor-α (1 ng/mL and 
25 ng/mL respectively). The explants were cultured in medium for 6 days and were 
digested for outcome measurements on the final day. On day 4, 35S-sulfate was added to 
the explant medium for later measurement of radiolabel incorporation as a measure of 
GAG biosynthesis. Cell viability was measured on day 5 using red/green fluorescent 
viability dyes fluorescein diacetate (FDA) which stains live cells green and propidium 
iodide (PI) which stains dead cells red.  
Results: Compared with untreated controls, explants subjected to the pro-inflammatory 
cytokines interleukin-1α and tumor necrosis factor-α exhibited greater 
glycosaminoglycan loss and a decrease in GAG biosynthesis. These treatments also 
decreased cell viability. Addition of dexamethasone improved cell viability compared to 
treatment with the cytokines. In addition, dexamethasone prevented glycosaminoglycan 
loss and increased GAG biosynthesis in the presence of interleukin-1α. However, 
dexamethasone did not prevent tumor necrosis factor-α mediated loss of GAGs.  
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Conclusion: These studies demonstrated that dexamethasone inhibited specific aspects of 
cartilage degradation associated with inflammation in early OA. This therapeutic 
counteracts the degradative changes initiated by inflammatory cytokines such as 
interleukin-1α without compromising cell viability. Future studies are needed to identify 
the mechanisms of dexamethasone action and the ideal concentration to use if it is to be 
used as a treatment for OA following acute joint injury. 
  
  viii 
TABLE OF CONTENTS 
 
TITLE……………………………………………………………………………………...i 
COPYRIGHT PAGE……………………………………………………………………...ii 
READER APPROVAL PAGE…………………………………………………………..iii 
ACKNOWLEDGMENTS ................................................................................................. iv 
ABSTRACT ........................................................................................................................ v 
TABLE OF CONTENTS ................................................................................................. viii 
LIST OF TABLES ............................................................................................................. xi 
LIST OF FIGURES .......................................................................................................... xii 
LIST OF ABBREVIATIONS .......................................................................................... xiii 
INTRODUCTION .............................................................................................................. 1 
Osteoarthritis Risk Factors and Prevalence .................................................................... 2 
Cartilage Function and ECM Composition..................................................................... 5 
Synovial Fluid and Nutrition of Cartilage ...................................................................... 6 
Types and Effects of Cartilage Injuries .......................................................................... 8 
Progression of OA......................................................................................................... 10 
Current Osteoarthritis Treatments ................................................................................. 11 
Overview of Present Study ........................................................................................... 15 
SPECIFIC AIMS .............................................................................................................. 16 
  ix 
METHODS ....................................................................................................................... 17 
Bovine cartilage harvest and culture ............................................................................. 17 
Exogenous cytokines and DEX treatments ................................................................... 18 
Matrix biosynthesis and biochemical analysis .............................................................. 19 
Calculations and statistical analyses ............................................................................. 21 
Viability ........................................................................................................................ 24 
RESULTS ......................................................................................................................... 26 
IL-1α increased sGAG loss and decreased sGAG biosynthesis in bovine cartilage 
explants ......................................................................................................................... 26 
DEX treatment reduced sGAG loss caused by IL-1α ................................................... 26 
Exogenous cytokine IL-1α decreases viability and DEX treatment improves viability 
of IL-1α treated explants ............................................................................................... 31 
Combination of exogenous cytokines IL-1α and TNF-α increased sGAG loss and 
decreased sGAG biosynthesis ....................................................................................... 32 
DEX treatment reduced sGAG loss caused by IL-1α but not TNF-α ........................... 32 
DEX ameliorates decrease in sGAG biosynthesis caused by IL-1α but not TNF-α ..... 33 
Exogenous cytokines IL-1α and TNF-α decrease viability and DEX treatment 
improves viability ......................................................................................................... 38 
DISCUSSION ................................................................................................................... 40 
Effects of IL-1 and TNF-α ............................................................................................ 41 
Effects of DEX .............................................................................................................. 42 
Targeting IL-1 and TNF-α with DEX ........................................................................... 42 
  x 
Alternative treatments to DEX alone ............................................................................ 42 
Other cytokines and combinations ................................................................................ 43 
Summary ....................................................................................................................... 43 
LIST OF JOURNAL ABBREVIATIONS........................................................................ 44 
REFERENCES ................................................................................................................. 45 
CURRICULUM VITAE ................................................................................................... 50 
 
  
  xi 
LIST OF TABLES 
 
Table Title Page 
1 Experimental treatment groups with cytokine and 
dexamethasone concentrations 
18 
2 sGAG assay volumes of tris buffer and sGAG standard 
and concentrations of sGAG standard 
20 
3 DNA assay volumes of tris buffer and DNA standard and 
concentration of DNA standard 
21 
4 Timeline of experiment separated into daily tasks 21 
5 sGAG assay example data of known concentrations and 
corresponding measured absorbance 
22 
6 DNA assay example data of known DNA concentrations 
and corresponding measured fluorescence 
23 
   
   
 
 
  
  xii 
 
LIST OF FIGURES 
 
Figure Title Page 
1 OA prevalence (incidence rate per 1000 people) with 
respect to age range plus type of joint and sex 
3 
2 Bovine knee joint with harvest area marked 17 
3 sGAG standard graph plotting measured absorbance 
versus known concentration of sGAG 
22 
4 Percent sGAG lost in cartilage explants increases with IL-
1α and decreases with DEX treatment 
27 
5 DNA content of explants did not differ significantly 
between treatments 
28 
6 sGAG biosynthesis normalized to wet weight decreases 
with IL-1α treatment and increases with DEX treatments 
29 
7 sGAG biosynthesis normalized to DNA content decreases 
with IL-1α treatment and increases with DEX treatments 
30 
8 Cell viability worsens with IL-1α treatment and improves 
with DEX treatment 
31 
9 Percent sGAG loss in cartilage explants increases with IL-
1α and TNF-α and decreases with DEX treatments 
34 
10 DNA content of explants did not differ significantly 
between IL-1α, TNF-α, and DEX treatments 
35 
11 sGAG biosynthesis normalized to wet weight decreases 
with IL-1α and TNF-α, and increases with DEX 
treatments 
36 
12 sGAG biosynthesis normalized to DNA content decreases 
with IL-1α, and TNF-α, and increases with DEX 
treatments 
37 
13 Cell viability worsens with IL-1α and TNF-α treatment 
and improves with DEX treatments 
38 
  
  xiii 
LIST OF ABBREVIATIONS 
 
ACL............................................................................................. Anterior cruciate ligament 
BMD ................................................................................................... Bone mineral density 
BMI ............................................................................................................ Body mass index 
BU ............................................................................................................ Boston University 
DEX ............................................................................................................. Dexamethasone 
DI .......................................................................................................................... Deionized 
DMMB ........................................................................................... Dimethylmethylene blue 
DMOAD ................................................................... Disease modifying osteoarthritis drug 
ECM ...................................................................................................... Extracellular matrix 
EtOH ......................................................................................................................... Ethanol 
FDA...................................................................................................... Fluorescein diacetate 
sGAG ....................................................................................... Sulfated glycosaminoglycan 
HA ................................................................................................................ Hyaluronic acid 
IGF ............................................................................................... Insulin-like growth factor 
IL .......................................................................................................................... Interleukin 
ITS............................................................................................. Insulin-transferrin-selenium 
MRI ......................................................................................... Magnetic resonance imaging 
NGF....................................................................................................... Nerve growth factor 
NSAID ....................................................................... Nonsteroidal anti-inflammatory drug 
OA .................................................................................................................... Osteoarthritis 
PBS .............................................................................................. Phosphate buffered saline 
  xiv 
PI ................................................................................................................ Propidium iodide 
PTOA ....................................................................................... Post-traumatic osteoarthritis 
PSA ............................................................................ Penicillin-streptomycin-amphotericin 
TGF ........................................................................................... Transforming growth factor 
TNF .................................................................................................... Tumor necrosis factor 
VEGF ............................................................................. Vascular endothelial growth factor 
WOMAC .............................. Western Ontario McMaster Universities Osteoarthritis Index 
 
 
 1 
INTRODUCTION 
 
Osteoarthritis (OA), a leading cause of disability worldwide affecting over 250 
million people, causes degradation of articular cartilage within joints (Ondrésik et al., 
2017). The clinical definition of OA focuses on joint symptoms with structural changes 
(Felson and Zhang, 1998). OA risk factors depend on factors such as genetics, age, 
gender, diet and weight to overuse, excessive loading, and joint injury (Ondrésik et al., 
2017). It is believed that in many cases, OA development is a result of multiple factors 
and, as such, makes diagnosis and treatment difficult (Felson, 2000). Because of the 
variety of risk factors, OA can be categorized into either a primary disease occurring over 
a patient’s lifetime or secondarily from chronic inflammation, metabolic disorders, or 
trauma or injury (post-traumatic OA or PTOA) (Ondrésik et al., 2017). PTOA is easier to 
treat because the cause can be traced to a single event, and treatment can begin 
immediately after the injury. Early treatment of OA is critical, as once the disease has 
progressed, the damage is often irreversible (Goldring, 2012).  
OA affects the entire joint, not just the cartilage often causing atypical bone 
growth leading to the formation of osteophytes (bone spurs) (Goldring, 2012). 
Inflammation of the synovium is also concomitant with OA progression (Goldring, 
2012). The synovial membrane, a sheet of connective tissue that lines the joint produces 
synovial fluid, which lubricates the joint and provides nutrients to the chondrocytes 
(cartilage cells). Bone spur formation and synovial inflammation is not only painful but 
also affects the alignment of the joint (Tuan and Korkusuz, 2016). Once OA has 
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progressed past the point of pain management, a knee or hip-replacement may be needed. 
In 2014, around 505,000 hip replacements and 723,000 knee replacements were 
performed in the U.S. (Lam et al., 2018).  
 
Osteoarthritis Risk Factors and Prevalence 
In the United States, OA of the knee occurs in roughly 19% of adults over the age 
of 45 with over 12 million of the total affected population aged 65 or older (Arden and 
Nevitt, 2006; Wallace et al., 2017). As mentioned previously, there are a number of risk 
factors for the development of OA. OA most commonly affects the knee joint and risk for 
OA development increases with age (Ondrésik et al., 2017). Over time, chondrocytes 
become less responsive to growth factors and tissue repair is less effective (Felson and 
Zhang, 1998). In addition, ligaments lose some of their rigidity with increasing age, 
compromising joint stability and increasing the risk for injury (Felson and Zhang, 1998). 
While both the hip and knee have an increased OA risk as age increases, hip OA 
development results from mechanical factors within the hip itself, whereas OA in the 
knee is correlated with the development of OA in other joints, indicating a more systemic 
predilection (Nicholls et al., 2011) (Arden and Nevitt, 2006).  
The Fallon Community Health Plan, a health maintenance organization, did a 
study from 1991-1992 to measure the incidence of OA in different joints at 10 ages 
ranges in both men and women (Felson and Zhang, 1998). Researchers Prieto-Alhambra 
et al. took data from Spain primary care records of adults over the age of 40 with a 
diagnosis of OA between 2006 and 2010 to analyze OA prevalence (Prieto-Alhambra et 
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al., 2014). Their data demonstrated that OA is more prevalent in men under the age of 
fifty but past fifty years of age, women are more likely to develop OA (Figure 1) (Felson, 
2000). Estrogen has protective role in the joint and has gained the attention of researchers 
since such a large number of post-menopausal women develop OA (Roman-Blas et al., 
2009). Estrogen decreases inflammation which protects the cartilage tissue from harmful 
molecules including reactive oxygen species (ROS) that are produced during the 
inflammatory response (Roman-Blas et al., 2009). Inflammation in cartilage results in 
increased production of NO and O2
- which can combine to form ROS including ONOO- 
and H2O2 (Henrotin et al.). The decrease in estrogen also leads to decreased muscle mass 
making the joint more susceptible to injury (Roman-Blas et al., 2009).  
    
Figure 1: OA prevalence (incidence rate per 1000 people) with respect to age range 
plus type of joint and sex. Solid lines represent total population, short dash line is 
women and long dash is men (Prieto-Alhambra et al., 2014). 
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There is also a genetic component of OA. When studying families with OA, there 
appears to be an association with a single base mutation in the gene for type II 
procollagen resulting in a chondrodysplasia (Knowlton et al.). In one family studied, OA 
presented as early as 16 years of age in the fingers and hips. Throughout the family, early 
onset OA appeared in joints throughout the arms, legs, and thorax (Knowlton et al.). 
Researchers Pan F et al. took 219 patients between ages 29 and 61 with children and 
evaluated knee pain using the Western Ontario and McMaster Universities Osteoarthritis 
Index (WOMAC) at two time points of 2 years and 10 years (Pan et al., 2016). At the 10 
year time point, children of parents with OA were more likely to experience knee pain 
than children whose parents did not have OA (Pan et al., 2016). 
The connection between bone density and OA development is currently unclear 
since studies have conflicting results. In some studies, patients with osteoporosis were 
less likely to develop OA which was thought to be due to the bone becoming softer and 
absorbing impact better (Felson and Zhang, 1998). Most studies indicate a higher bone 
mineral density is a risk factor for OA development. Studies have shown that women 
with OA in the hip or knee also have a higher bone mineral density (BMD) near the 
afflicted joints (Nicholls et al., 2011). In addition, microfractures that result from 
excessive loading on joints can occur in increased BMD stressing cartilage during joint 
loading, which leads to OA formation (Arden and Nevitt, 2006).  
Obesity and metabolic syndromes are another risk factor for OA (Ondrésik et al., 
2017). One reason for this is the excessive stress of the joints, particularly the knee joint 
(Messier et al.). While this is one reason, there is also a correlation between obesity and 
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OA of the hand, suggesting the cause might also be tied to metabolism or inflammation 
(Allen and Golightly, 2015). Researchers Fowler-Brown et al. studied the effects of 
leptin, a pro-inflammatory cytokine secreted by adipose tissue on body mass index (BMI) 
and osteoarthritis of the knee (Fowler-Brown et al., 2015). They discovered that a BMI 
increase of 5 kg/m correlated with a 32% increased risk of knee OA development, while a 
200 pM increase in serum leptin correlated with an 11% increased risk of OA (Fowler-
Brown et al., 2015).  
 
Cartilage Function and ECM Composition 
 Articular cartilage provides a surface for bones to move across one another and 
provides mechanical support to withstand substantial loads (Sophia Fox et al., 2009). The 
primary cell type in cartilage is the chondrocyte, which synthesizes and assembles an 
extracellular matrix (ECM). This matrix provides for mechanical resistance to 
compressive, tensile, and shear loading, but the high matrix density also restricts the 
permeation of molecules (including therapeutics) through the tissue (Sophia Fox et al., 
2009). This matrix includes macromolecules such as type II collagen and proteoglycans 
which have many sulfated glycosaminoglycans (sGAGs). sGAG chains consist of 
disaccharides and attach covalently to a central core protein to form a proteoglycan (Tuan 
and Korkusuz, 2016). The GAG chains contain many ionized carboxyl and sulfate groups 
giving an overall high negative charge to the matrix (Jackson and Gu, 2009). Collagen 
serves to provide tensile and shear stability to the tissue while the proteoglycans serve to 
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offer osmotic properties that ensure the cartilage can withstand the compressive loads 
placed on it (Sophia Fox et al., 2009).  
 The production and degradation of these matrix macromolecules are regulated by 
a variety of proteins such as growth factors and regulatory peptides (Sophia Fox et al., 
2009). The balance of ECM degradation and synthesis is critical to the homeostasis and 
the health and stability of cartilage. For example, interleukin-1 (IL-1) promotes 
catabolism of the matrix macromolecules and suppresses the transcription of these same 
macromolecules (Tuan and Korkusuz, 2016). Other protein growth factors, such as 
insulin-like growth factor-1 (IGF-1) and transforming growth factor beta (TGF-β), 
decrease catabolism and promote the synthesis of new ECM macromolecules (Tuan and 
Korkusuz, 2016). After a joint injury or in chronic joint diseases, cytokines such as tumor 
necrosis factor-α (TNF-α) and the interleukins are present at higher levels, making them 
attractive targets for therapies for treating problems of the joint (Tuan and Korkusuz, 
2016).  
 
Synovial Fluid and Nutrition of Cartilage  
Cartilage differs from many other tissues due to its lack of blood supply and 
instead relies on diffusion of water and nutrients from the synovial fluid into the tissue 
(Sophia Fox et al., 2009). Synovial fluid is comprised of water and proteins. Hyaluronic 
acid (HA) is a non-sulfated glycosaminoglycan in the synovial fluid, and is a key 
component that gives synovial fluid its lubricating and viscoelastic properties (Balazs, 
1982). The concentration of HA in the synovial fluid is high and because these molecules 
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occupy a large volume they overlap to form a network, which excludes larger molecules 
and changes the chemical activity of molecules present in the fluid (Balazs, 1982). This 
property potentially impacts the delivery of injectable therapeutics into joint spaces. 
Because HA increases the viscosity of the synovial fluid between opposing joint 
surfaces, HA is critical in joint lubrication for both soft tissues (ligaments and synovial 
tissue), and cartilage for cartilage movement (Balazs, 1982). The protection offered by 
HA is compromised when the joint experiences inflammation, since there is a decrease in 
the number of HA molecules, which allows movement of macromolecules leading to a 
less stable ECM (Balazs, 1982). In addition to HA, an important glycoprotein called 
lubricin, found in the superficial zone of cartilage and in the film overlying cartilage, also 
plays an important role in joint lubrication (Jay and Waller, 2014).  
The negative charge in the cartilage tissue matrix attracts positive ions dissolved 
in interstitial water including Na+ which helps maintain electroneutrality and regulates 
tissue swelling effects (Jackson and Gu, 2009). The ECM fibers (collagen, elastin, and 
proteoglycan network) act like a sponge, holding water in the cartilage tissue (Tuan and 
Korkusuz, 2016). When the joint is loaded, the ECM fibers are compressed, resulting in 
the net motion of the water molecules out of cartilage like that of a compressed sponge 
(Tuan and Korkusuz, 2016). When the load is removed, the fluid then re-enters the 
cartilage, and this re-imbibed water enhances uptake of fresh nutrients from the joint 
space. Thus, joint motion provides nourishment to the cartilage tissue and allows for a 
resistance to compression and return to form; these are qualities critical for the ability of 
cartilage to withstand pressure.  
 8 
Types and Effects of Cartilage Injuries 
Loading of a joint with weight leads to the movement of fluid within the cartilage 
ECM which helps to distributes mechanical loading stresses across the joint surface and 
prevents damage to the cartilage and underlying bone (Buckwalter, 2002). In addition, 
the surrounding muscles stabilize the joint. With sudden movements, the ECM fluid does 
not adequately distribute throughout the matrix, leading to a higher amount of force being 
directed to the cartilage directly, potentially minimizing the ability of the joint to 
distribute weight and withstand impact (Buckwalter, 2002). In addition, damaging forces 
to cartilage can change the ECM composition since tissue damage can lead to altered 
protein synthesis rate and cartilaginous properties. Such changes often appear before any 
visible damage to the cartilage is detected (Buckwalter, 2002). Unfortunately, the ability 
to identify cellular changes, in the clinic, is not currently available, although surgeons can 
often recognize a difference in consistency of cartilage that is undergoing ECM 
composition changes (Buckwalter, 2002).  
There are several types of cartilage injuries, including osteochondral fractures 
(which include the articular surface and bone), cartilage damage, and chondral and matrix 
micro-damage without visible macroscopic damage that may be visible during 
arthroscopy (Wang and Grodzinsky, 2015). Damage to cartilage is assessed via magnetic 
resonance imaging (MRI) or arthroscopy, but injuries in the absence of visible damage to 
cartilage or bone are harder to detect (Buckwalter, 2002; Wang and Grodzinsky, 2015). 
Injuries of the cartilage often accompany injuries of other joint tissues such as 
surrounding muscle, ligaments, bone, and the synovium (Buckwalter, 2002).  
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Chondral fractures are fractures of the articular cartilage surrounding a bone, 
whereas an osteochondral fracture includes both the cartilage and the bone (Buckwalter, 
2002). Osteochondral fractures are more likely to occur in children or young adults while 
chondral fractures are more common in adults with a mature skeleton (Buckwalter, 
2002). This is likely because in an immature skeleton, mechanical properties that protect 
the cartilage from damage, such as calcification and cartilage stiffness, are not yet well 
developed (Flachsmann et al., 2000). Injuries of the osteochondral type are often more 
severe, especially since injury to bone also involves the blood supply (Buckwalter, 2002). 
This can result in bleeding and clotting and an elevated inflammatory response. 
Even in cases without a fracture, initiation of permanent cartilage degradation 
may be present. In instances without a visible osteochondral or chondral fracture 
following an anterior cruciate ligament (ACL) rupture, a biopsy may show loss of ECM 
macromolecules or cell death (Wang and Grodzinsky, 2015). This indicates that 
development of post-traumatic osteoarthritis (PTOA) might begin before there is even a 
clinically diagnosed cartilage injury. ACL rupture causes several effects. While the 
cartilage matrix normally is well hydrated, following ACL rupture, there is a further 
increase in this hydration leading to swelling (Wang and Grodzinsky, 2015). In addition, 
the sGAG content of the ECM becomes much lower following this type of injury (Simon 
et al., 2015). There is also a clear increase in proinflammatory cytokines including IL-1α 
and TNF-α (Haslauer et al., 2014).  
 10 
Progression of OA  
In adults, chondrocytes maintain a relatively low ECM turnover rate, but with the 
development of OA, they can be stimulated to favor catabolic activity when the tissue is 
under stress (Ondrésik et al., 2017). It is believed that this increase in catabolism is to 
promote injury repair (Loeser et al., 2012). Activated chondrocytes release cytokines and 
proteases which begin to break down the ECM producing debris within the tissue space 
(Ondrésik et al., 2017). The breakdown of ECM molecules compromises the elasticity 
and strength of the cartilage (Goldring, 2012). Cartilage can withstand a certain degree of 
degradation due to the density of the proteoglycan network, but joint injury can cause the 
collagen type II molecules to be degraded, leading to irreversible damage (Goldring, 
2012). The cytokines produced by the chondrocytes induce an inflammatory response, 
and the upregulated cytokines can also lead to the generation of reactive oxygen species 
including nitric oxide and superoxide anion both of which lead to further breakdown of 
the ECM (Ondrésik et al., 2017). As a result, there is an increase in growth factors such 
as vascular endothelial growth factor (VEGF) and nerve growth factor (NGF). VEGF and 
NGF come from the underlying bone to remodel and repair the cartilage tissue (Ondrésik 
et al., 2017). Because cartilage is avascular, the signal for new blood vessels induced by 
VEGF compromise the integrity of the tissue (Ondrésik et al., 2017). This entire process 
can lead to destruction of not only the cartilage, itself, but also the synovial membrane 
(Ondrésik et al., 2017). 
When an acute joint injury leads to PTOA, the injury usually involves an impact 
to the articular surface (Anderson et al., 2011). In a joint with pathologies such as OA or 
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PTOA, the synovial fluid no longer has rheological properties that normally would 
provide protection to synovial tissue and cartilage making the tissues even more 
susceptible to mechanical damage often exacerbating OA progression (Balazs, 1982).   
 
Current Osteoarthritis Treatments 
Current treatment for OA involves three pieces: relief, repair, and replace 
(Ondrésik et al., 2017). Relief requires treatment of earlier stages of OA and often entails 
lifestyle modifications coupled with pharmacologic therapies for pain. Lifestyle 
modifications include exercise and weight loss while most pharmacologic treatments 
include an opioid or analgesic (Ondrésik et al., 2017). Because of the lack of blood 
supply, treatment of OA with drugs that rely on blood circulation to reach their targets 
(e.g. cartilage) is not efficient (Ondrésik et al., 2017). This makes OA much harder to 
treat leading researchers to examine new drugs and new drug carriers to overcome the 
barrier of delivering therapeutics into cartilage tissue (Karsdal et al., 2016). Currently, the 
most effective pharmacological treatments for OA pain are nonsteroidal anti-
inflammatory drugs (NSAIDs) which reduce inflammation and pain in the tissues 
surrounding the joint but come with potential risks including gastrointestinal 
complications and increased bleeding (Lanas et al., 2011). However, there is still no 
FDA-approved drug that can halt or reverse progression of the disease.  
Another treatment option, if pharmaceuticals do not work, is 
viscosupplementation, an injection of a viscoelastic solution of hyaluronic acid into the 
joint space to bring the synovial fluid properties back to normal (Ondrésik et al., 2017). 
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As stated previously, OA leads to a change in the rheological properties of the synovial 
fluid due to a decrease in the amount of hyaluronic acid present in the ECM. However, 
studies have shown that this treatment for pain is not necessarily more effective than 
NSAIDs and only works in the short-term but, does have fewer risks than NSAIDs 
(Bannuru et al., 2014).  
The next stage of treatment, repair, involves arthroscopy, surgical procedures, and 
regenerative medicine (Ondrésik et al., 2017). Current research focuses on investigating 
regenerative medicine in the form of stem cells and scaffolding to regrow a patient’s 
cartilage (Ondrésik et al., 2017). One way to do that is to develop microsphere of 
scaffolding containing stem cells (Ahearne and Kelly, 2013). Depending on the material, 
the microspheres promote cell proliferation that can be delivered into the damaged 
cartilage site (Ahearne and Kelly, 2013). Currently, when performing these experiments, 
progenitor cells are harvested from the patient (an animal model), cultured, and re-
implanted into the desired site (Ahearne and Kelly, 2013). Further research is needed to 
fine-tune the process prior to human trials. Surgical procedures typically involve 
debridement where the surgeon removes diseased and inflamed tissue to alleviate the pain 
(Seed et al., 2009). However, there are no data to support the idea that debridement helps 
more than pharmacological treatment in relieving symptoms and improving functionality 
(Seed et al., 2009).  
The final stage of treatment is to replace. Here, the surgeon may elect to graft the 
patient’s own cartilage from one location into the damaged site or in the most severe 
cases, replace the whole knee (Ondrésik et al., 2017). Knee replacement, or arthroplasty, 
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is the most effective treatment for improving functionality and reducing pain (Seed et al., 
2009).  
The above treatments mainly focus on the pain and inflammatory symptoms 
without slowing or halting the degradation of cartilage matrix (Bajpayee et al., 2014). 
Pharmaceutical companies continue to search for therapeutics to that are disease-
modifying osteoarthritis drugs (DMOADs) (Bajpayee and Grodzinsky, 2017). These 
drugs are anti-catabolic and pro-anabolic therapeutics that target the proteases and 
cytokines released in response to cartilage damage (Bajpayee and Grodzinsky, 2017). 
DMOADs also target components of the bone remodeling process and the inflammation 
process (Bajpayee and Grodzinsky, 2017). The goal is to minimize breakdown of 
cartilage as much as possible while also targeting the other processes that lead to severe 
OA.  
Although some of the DMOAD therapeutics have shown promise in halting the 
progression of OA, none have been approved due to systemic toxicity (Bajpayee et al., 
2014). As mentioned previously, delivering therapeutics into cartilaginous spaces proves 
difficult since cartilage is avascular. Simply injecting pharmaceuticals into a joint capsule 
often results in little therapeutic reaching the target site since the drug is rapidly cleared 
from the space via capillaries beneath the synovium and the lymphatic system (Bajpayee 
and Grodzinsky, 2017). This problem applies to pain medication requiring high doses to 
be injected, which increases the risk of systemic toxicity (Bajpayee and Grodzinsky, 
2017). Furthermore, even if the drug remains in the joint space, achieving full penetration 
into the cartilage tissue at sufficient levels to reach the therapeutic threshold provides 
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another obstacle. To bypass these issues, research is being conducted on novel drug 
delivery mechanisms. A key approach to cartilage drug delivery is to take advantage of is 
the high negative charge density of the sGAGs within the extracellular matrix.  
When exploring possible drug carriers for cartilage, a few properties need to be 
considered. First, since sGAG chains are a major component of cartilage tissue, cartilage 
overall is negatively charged, and a positively charged nano-carrier (for example a small 
cationic protein) can be effective. Second, the binding affinity of the protein within the 
matrix must be considered, since the carrier will likely be binding the sGAGs to be 
retained and then deliver the therapeutic inside the cartilage. While we want the carrier to 
bind sGAGs, if this binding were too strong (i.e. covalent), the carrier would not 
penetrate the full thickness of the cartilage and would be ineffective (Bajpayee and 
Grodzinsky, 2017). Thus, a protein carrier with sufficient affinity but reversible binding 
is preferred. Finally, the protein must be small enough to navigate the small spaces 
between sGAGs reported to be less than 10-15 nm in diameter (Bajpayee and 
Grodzinsky, 2017).  
Avidin is an example of a protein used to study this delivery mechanism since it is 
positively charged and small enough to penetrate through cartilage (Bajpayee et al., 
2014). It also binds reversibly ensuring retention in the cartilage matrix while not staying 
bound in the outer edge of cartilage as previously discussed (Sophia Fox et al., 2009). 
Once Avidin showed promise as a potential carrier, researchers then conjugated the 
protein with dexamethasone (DEX) (Bajpayee et al., 2016). DEX is an anti-catabolic 
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glucocorticoid and has promise in treating some of the negative effects of cartilage injury, 
mentioned earlier (Bajpayee et al., 2016).  
 
Overview of Present Study 
The goal of this project was to examine the impact of DEX on cytokine mediated 
degradation of cartilage using a bovine explant model. This is done by first treating 
cartilage explants with inflammatory cytokines IL-1α and TNF-α. Assays such as DMMB 
dye binding assay to measure total GAG content, DNA content assays using Hoechst 
33258 dye, and radiolabel incorporation assays for matrix biosynthesis are used to 
measure cell health and how much the cytokines may have adversely affected them. 
Since cytokines can upregulate proteases that lead to the breakdown of matrix 
macromolecules in the ECM, measuring sGAG content in both the tissue explants and the 
media will allow for calculation of how much of the aggrecan GAG was lost from the 
explants. The DNA content assesses cell number and enables determination of 
consistency among explants throughout all the groups. Since DNA is used for 
normalization of cell biosynthesis on a per-cell basis, it is helpful that the explant size 
(measured via wet weight) is relatively consistent across all groups. Scintillation counting 
of 35S-sulfate enables an estimate of the rate of synthesis of sulfated GAGs which can 
then be used to assess the metabolic rate of the cells. This metabolic rate is indicative of 
cell health. The explants are also treated with DEX to see if matrix degradation is halted 
or reversed when cytokine-treated explants are compared with control explants. In 
addition to these assays, cell viability is assessed between treatment groups.   
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SPECIFIC AIMS 
 
 There are currently no effective therapies of OA. OA treatment options include 
NSAIDs for overall pain management or injection of pain medication directly into joints 
affected by OA. While the treatment of inflammation with a glucocorticoid may be 
effective, it is uncertain what the effect is on chondrocyte cell viability and on the 
progression of OA itself. In order to further investigate the effect of glucocorticoids, I 
will:  
 
1. Examine effects of inflammatory cytokines on sGAG protein loss and 
biosynthesis and DNA content in cartilage tissue 
2. Treat cartilage explants with glucocorticoids to examine effect on cytokine-
mediated sGAG loss and biosynthesis and DNA content 
3. Utilize fluorescence to determine viability of cartilage cells after treatments with 
cytokines and glucocorticoids 
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METHODS 
 
Bovine cartilage harvest and culture 
Cartilage explants were harvested from 1-2-week-old (newborn) bovine knee 
joints. Excess muscle tissue was first cut away using a scalpel with a #10-blade, and the 
muscle near the femur was removed down to the bone, allowing for removal of the distal 
femur. The leg was then mounted on a holder to stabilize it. The ligaments attached to the 
tibia and fibula were then severed to allow for removal of the lower leg below the knee. 
In order to obtain the cartilage explants, the topmost layer of soft tissue was removed 
from the knee joint prior to harvesting. The knee joint after the tissue was cleared to 
reveal the femoropatellar cartilage is shown in Figure 2. Cartilage disk explants were 
obtained using a 3 mm dermal punch. The dermal punch removed cartilage plugs from 
the area indicated by dashed lines (Figure 2).  
 
Figure 2: Bovine knee joint with harvest area marked: The dashed circles indicate the 
area from which the explant plugs were removed  
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Plugs were then placed into wells of a 96-well plate containing 300 μL of 
phosphate buffered saline (PBS) and penicillin-streptomycin-amphotericin B (PSA) in 
each well to rinse the plugs. Discs were trimmed to be 1 mm thickness utilizing a 
stainless-steel template and a razor blade, resulting in 3 mm by 1 mm cylindrical explant 
disks. These explants included the topmost superficial zone of the cartilage tissue. 
After harvest and trimming, explants were placed into a new 96-well tray filled 
with 300 μL media and equilibrated for two days in a 37°C incubator (named day -2). 
Medium consisted of low-glucose DMEM, 0.1 mM HEPES buffer, 0.5 mL of 1 μM 
nonessential amino acids, 1.6 μM proline, 0.8 μg/mL ascorbic acid, and a mixture of 1 
units/mL penicillin G, 1 μg/mL streptomycin, and 2.5 ng/mL amphotericin. The medium 
was supplemented with 1% ITS (containing insulin (0.1 μg/mL), transferrin (0.055 
μg/mL), and selenium (0.05 ng/mL)). Each well was filled with 300 μL of medium.  
 
Exogenous cytokines and DEX treatments 
Cartilage explants were divided into groups containing 6 explants. Two additional 
explants per treatment group were used for cell viability. The experimental groups are 
depicted below in Table 1. 
Table 1: Experimental treatment groups with cytokine and dexamethasone 
concentrations: Pluses indicate treatment was present and minuses indicate treatment 
was absent 
IL-1α (ng/mL) - 1 10 - 1 10 1 - 
TNFα (ng/mL) - - - - - - 25 25 
DEX (nM) - - - 100 100 100 - 100 
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The cytokines (IL-1α and TNFα) and DEX were added after a two-day pre-
equilibration in culture medium. Stock DEX solutions were made by first adding 0.5 mg 
of DEX powder (Sigma Aldrich) to 0.5 mL of ethanol (EtOH) and stored at 4°C. The 
stock was diluted in water prior to adding to cell cultures. The explants were cultured for 
an additional six days, changing medium every two days. All medium was saved and 
stored in the freezer for measurement of sGAG release.  
 
Matrix biosynthesis and biochemical analysis 
After four days of culture with cytokines and DEX, 35S-sulfate (Perkin Elmer, 5 
μCi) was added to the medium to measure sGAG biosynthesis rates within explants via 
radiolabel incorporation. As a standard, 1 mL of medium was saved for calculation of 
radiolabel concentration. Radiolabel incorporation of the explants and the radiolabel 
concentration in the medium were measured using a liquid scintillation counter. After a 
total of 6 days of culture in the presence and absence of ±IL-1α, ±TNFα, and ±DEX, the 
explants were transferred into pre-weighed tubes and then re-weighed. This weight was 
used to normalize the DNA concentration and 35S-radiolabel incorporation rate. The 
explants were then washed with a PBS Rx wash solution of 460 mg of proline, 1.42 g of 
sodium sulfate, and 40 mL of PBS. This Rx solution was diluted 1:250 in PBS and used 
to wash the explants four times at 20 minutes each wash. This wash cleared out the free 
radiolabel that was not incorporated into the structure of the newly synthesized sGAG 
and stop incorporation of radiolabel at 48 hours. Proteinase K (0.1 mg/mL) in tris buffer 
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pH 8 with CaCl2 (5 nM) was then added and the tubes, and the tubes were placed into a 
60°C water bath overnight to digest the explants.  
The content of sGAG in the tissue digests (as well as that in the remaining 
medium) was measured via a dimethylmethylene blue (DMMB) dye-binding assay 
(Coulson-Thomas and Gesteira). This assay was performed on all medium collected and 
on the digested explants. Digested explant samples were diluted via a 1:10 dilution prior 
to the assay. The standard concentrations are shown in the table below. sGAG standards 
are made from shark CS powder (1 mg/mL) (Sigma Aldrich). 
Table 2: sGAG assay volumes of tris buffer and sGAG standard and concentrations 
of sGAG standard 
Tube No. Tris Buffer (μL) sGAG standard/transfer (μL) [sGAG] (μg/mL) 
1 800  200 μL (stock) 200  
2 100 100 μL from tube 1 100 
3 100 100 μL from tube 2 50 
4 100 100 μL from tube 3 25 
5 100 100 μL from tube 4 12.5 
6 100 100 μL from tube 5 6.25 
7 100 100 μL from tube 6 3.125 
8 100 100 μL from tube 7 1.5625 
9 100 0 0 
 
DNA content in each tissue digest was measured using Hoechst 33258 
bisbenzimidiazole fluorescent dye. This assay was performed on only the digested 
explants, and a 1:3 dilution was done prior to conducting the assay. The DNA dye used 
contained deionized (DI) water, 10x TEN buffer (73 μM), and Hoechst 33258 dye (0.1 
μg/mL). The DNA standard concentrations are shown below.  
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Table 3: DNA assay volumes of tris buffer and DNA standard and concentration of 
DNA standard 
Tube No. Tris Buffer (μL) DNA standard (μL) [DNA] (μg/mL) 
1 0 200 10 
2 100 100 5 
3 120 80 4 
4 140 60 3 
5 160 40 2 
6 180 20 1 
7 200 0 0 
 
Table 4 summarizes the experimental timeline. Day -2 corresponds to the start of 
the 2-day pre-equilibration period before treatments were initiated.    
Table 4: Timeline of experiment separated into daily tasks 
Day -2 Harvest cartilage from bovine knee, trim explants to uniform length, put 
explants in media (no treatments) 
Day 0 Remove media (store in freezer), add new media with cytokines and DEX 
treatment 
Day 2 Remove media (store in freezer), add new media 
Day 4 Remove media (store in freezer), add new media with 35S-sulfate radiolabel 
Day 5 Conduct viability, weigh tubes  
Day 6 Remove media (store in freezer), wash explants with Rx wash, dry explants 
and place in tubes, add proteinase K to digest, place in 50°C bath  
Day 7 Remove tubes from bath, conduct sGAG assay, DNA content, and 
scintillation for measurement of radiolabel uptake 
 
Calculations and statistical analyses 
A standard curve was created using nine sGAG standard concentrations and the 
corresponding absorbance at a wavelength of 520 nm. The graph was fitted with a second 
order polynomial line of best fit. The equation of the line was used to obtain coefficients 
that were used in the quadratic formula to take the measured absorbance value and 
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calculate the concentration for all data points. An example of concentration and 
corresponding absorbance values, and the graph are shown below.  
Table 5: sGAG assay example data of known sGAG concentrations and 
corresponding measured absorbance 
sGAG Concentration (μg/mL) Absorbance 
200 0.3224 
100 0.2974 
50 0.2229 
25 0.1104 
12.5 0.0634 
6.25 0.0304 
3.125 0.0144 
1.5625 0.0064 
0 0 
 
 
Figure 3: sGAG standard graph plotting measured absorbance versus known 
concentration of sGAG: This graph is used to obtain an equation that can then be used 
to calculate the concentration of sGAG given an absorbance value at wavelength 520 nm. 
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Once the sGAG content was found for each medium sample and that of the 
digested explants, the total sGAG content was calculated by adding all the sGAG 
concentrations together corresponding to that explant. Adding the sGAG concentrations 
for all the medium changes together yields the total sGAG lost during the 6-day culture 
period. The percent sGAG lost is then calculated by dividing the sGAG lost to the 
medium by the total sGAG content (explant plus medium). (Because the volume of 
medium is only 300 μL, the value obtained for the sGAG concentration in the medium 
samples must be multiplied by 0.3. In addition, because the explant digests were diluted 
1:10, the sGAG concentration for the explant samples needs to be multiplied by 10.) 
A DNA standard curve was used to calculate the DNA concentration in the 
explant samples. An example table with concentration and fluorescence for DNA is 
shown below (Table 6). The equation used to calculate the DNA concentration is the 
same as that for the sGAG concentration.  
Table 6: DNA assay example data of known DNA concentrations and corresponding 
measured fluorescence 
DNA Concentration (μg/mL) Fluorescence 
10 6738 
5 3858 
4 3248 
3 2611 
2 2011 
1 1642 
0 1067 
 
sGAG biosynthesis rates were calculated from the scintillation data using the 
equation below. 
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𝑏𝑖𝑜𝑠𝑦𝑛𝑡ℎ𝑒𝑠𝑖𝑠 𝑟𝑎𝑡𝑒 [
𝑝𝑚𝑜𝑙
ℎ𝑟
𝜇𝑔 𝐷𝑁𝐴
] =
𝑠𝑎𝑚𝑝𝑙𝑒 𝑟𝑒𝑎𝑑𝑖𝑛𝑔
𝑚𝑒𝑑𝑖𝑎 𝑟𝑒𝑎𝑑𝑖𝑛𝑔 ∗ 814
𝑛𝑚𝑜𝑙
𝑚𝐿 ∗ 1 𝑚𝐿 ∗
1000 𝑝𝑚𝑜𝑙
𝑛𝑚𝑜𝑙
48ℎ𝑟
[𝐷𝑁𝐴] 𝑖𝑛 𝜇𝑔
 
 
The sample reading is the value obtained for the digested explant from liquid 
scintillation counting, while the medium reading is the value obtained for the saved 
medium. The volume of digested explant is 1 mL, 48 hours is the time for incubation 
with 35S-sulfate, and 1,000 is the conversion between nmol and pmol. The 814 nmol/mL 
value is the total sulfate concentration in the cell culture medium. The final value is 
normalized to the DNA concentration and the weight of the explant. Normalization to 
both was done to ensure results were consistent. 
After values were calculated for percent sGAG loss, DNA concentration, and 
sGAG biosynthesis rate, two-way ANOVA was performed on the means to determine 
statistical significance between treatment groups. Statistical significance was taken as p < 
0.05.  
 
Viability  
 To determine the effect of treatment on cell viability, explants prepared and 
stained using cell viability dye. First, a dye solution was made consisting of fluorescein 
diacetate (FDA) (3.0 μg/mL), propidium iodide (PI) (5.0 μg/mL), and PBS. The FDA 
was used to visualize live cells (green fluorescence) and the PI was used for dead cells 
(red fluorescence). Explants slices 100 microns thick were first prepared by hand 
utilizing a scalpel with a #11 blade and forceps and placed on a microscope slide. Then, 
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the dye solution was added and removed after 3 minutes. The explants were washed with 
PBS for 2 minutes. Then, visualization under the microscope was conducted.    
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RESULTS 
 
IL-1α increased sGAG loss and decreased sGAG biosynthesis in bovine cartilage 
explants 
Experiments were performed to determine effects of IL-1α on sGAG loss and 
biosynthesis. Addition of IL-1α led to a dose dependent increase in percent sGAG loss 
from the cartilage into the medium (16.3% ± 1.8% at 1 ng/mL of IL-1α (p < 0.003) and 
20.5% ± 2.1% at 10 ng/mL of IL-1α (p < 0.001)) versus the untreated condition (11.8% ± 
1.4%) (Figure 4). 
sGAG biosynthesis rates in cartilage explants were measured by 35S-sulfate 
incorporation assays. The sGAG biosynthesis rate was normalized to both DNA content 
(Figure 5) and wet weight and the two were compared to ensure results were consistent 
(Figure 6 and 7). IL-1α treatment decreased radiolabel incorporation (biosynthesis) (20.7 
± 4.0 pmol/hr/mg wet weight at 1 ng/mL of IL-1α (p < 0.004) and 12.5 ± 1.1 pmol/hr/mg 
wet weight at 10 ng/mL of IL-1α (p < 0.001)) compared with the control condition (26.6 
± 3.3 pmol/hr/mg wet weight) (Figure 7).  
 
DEX treatment reduced sGAG loss caused by IL-1α 
 Addition of IL-1α led to a greater sGAG loss from the explant to the medium. The 
addition of DEX at 100 nM led to a small decrease in the percent sGAG loss from 11.8% 
± 1.4% in the control condition to 9.7% ± 1.2%. In the IL-1α condition at 1 ng/mL, DEX 
decreased the percent sGAG loss from 16.3% ± 1.8% to 12.6% ± 1.8% (p < 0.0002) 
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(Figure 4). In the IL-1α condition at 10 ng/mL, DEX decreased the percent sGAG loss 
from 20.6% ± 2.1% to 18.1% ± 3.1% (p < 0.0002) (Figure 4).   
 
Figure 4: Percent sGAG lost in cartilage explants increases with IL-1α and 
decreases with DEX treatment: Percent sGAG loss measured from immature bovine 
cartilage after a 6-day culture. Disks were treated with IL-1α at two doses (1 ng/mL and 
10 ng/mL) with and without DEX at 100 nM. Each group had n = 6 explants. * vs 
untreated control (p < 0.0001), # vs 1 ng/mL (p < 0.0001), $ (p < 0.0001). 
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Figure 5: DNA content of explants did not differ significantly between treatments: 
Graph depicting DNA content measured for the various groups. This DNA is normalized 
to wet weight. This demonstrates that the DNA content is consistent across treatment 
groups. No statistical differences among groups were found. 
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Figure 6: sGAG biosynthesis normalized to wet weight decreases with IL-1α 
treatment and increases with DEX treatments. * vs untreated control (p < 0.0001), # 
vs 1 ng/mL (p < 0.0001), $ (p < 0.0001). 
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Figure 7: sGAG biosynthesis normalized to DNA content (shown in Figure 5) 
decreases with IL-1α treatment and increases with DEX treatments. * vs untreated 
control (p < 0.0001), # vs 1 ng/mL (p < 0.0001), $ (p < 0.0001). 
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Exogenous cytokine IL-1α decreases viability and DEX treatment improves viability 
of IL-1α treated explants 
 Control IL-1α 
1 ng/mL 
IL-1α  
10 ng/mL 
No DEX 
   
DEX  
100 nM 
   
Figure 8: Cell viability worsens with IL-1α treatment and improves with DEX 
treatment: Viability tests were conducted on day 5. Images 1-3 show explants that did 
not receive DEX treatments and 4-6 received 100 nM of DEX. PI was used to stain dead 
cells red and FDA stained live cells green.  
Addition of IL-1α led to a decrease in cell viability as indicated by the increase in 
red fluorescence (Figure 8 compare 2 and 3 with and 1). Addition of DEX did not alter 
cell viability (Figure 8 compare 1 and 4). However, DEX showed an improvement in cell 
viability when in comparison with the IL-1α treated groups (Figure 8 compare 4 with 5 
and 6). 
 
1 2 3 
4 5 6 
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Combination of exogenous cytokines IL-1α and TNF-α increased sGAG loss and 
decreased sGAG biosynthesis 
An experiment was also performed to see the combined effects of TNF-α and IL-
1α on sGAG loss and biosynthesis. Addition of the two cytokines together led to an 
increase in percent sGAG loss from the cartilage into the medium (14.9% ± 0.9% at 1 
ng/mL of IL-1α and 25 ng/mL of TNF-α) versus the untreated condition (9.7% ± 0.9%). 
(Figure 9).  
As before, sGAG biosynthesis was normalized to both DNA content (Figure 10) 
and wet weight to ensure consistent results (Figure 11 and Figure 12). Addition of TNF-α 
and IL-1α together led to a decrease in sGAG biosynthesis (38.3 ± 6.9 pmol/hr/mg wet 
weight at 1 ng/mL of IL-1α and 25 ng/mL of TNF-α) compared to the control condition 
(84.7 ± 4.1 pmol/hr/mg wet weight). (Figure 11).  
 
DEX treatment reduced sGAG loss caused by IL-1α but not TNF-α  
With the effect of combined cytokine treatment on sGAG loss established, DEX 
was added to medium containing both IL-1α and TNF-α. With the two cytokines 
together, there was no decrease in sGAG loss (17.1% ± 1.4% for DEX treatment versus 
14.8% ± 0.9% with just cytokines) (Figure 9). Addition of just DEX showed a percent 
sGAG loss similar to that of the control (Figure 9). The addition of DEX to just IL-1α did 
bring percent sGAG loss closer to the control (Figure 9). In addition, DEX added to just 
TNF-α yielded a similar value of percent sGAG loss to that of just the cytokines (Figure 
9).  
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DEX ameliorates decrease in sGAG biosynthesis caused by IL-1α but not TNF-α  
When DEX was added to media consisting of both IL-1α and TNF-α, there was 
no increase in sGAG biosynthesis compared to the addition of just the cytokines (21.6 ± 
4.1 pmol/hr/mg wet weight versus 38.3 ± 6.9 pmol/hr/mg wet weight for IL-1α + TNF-α) 
(Figure 11). The effect on sGAG biosynthesis of just DEX alone was similar to that of 
the control (71.3 ± 14.5 pmol/hr/mg wet weight for DEX versus 84.7 ± 6.9 pmol/hr/mg 
wet weight for control) (Figure 11). Addition of DEX to medium containing just IL-1α 
brought the biosynthesis rate closer to the control (83.3 ± 8.4 pmol/hr/mg wet weight for 
DEX + IL-1α versus 84.7 ± 6.9 pmol/hr/mg wet weight for control). Addition of DEX to 
media containing just TNF-α yielded a biosynthesis rate closer to that of just the 
cytokines (21.7 ± 4.0 pmol/hr/mg wet weight for DEX + TNF-α versus 38.3 ± 6.9 
pmol/hr/mg wet weight for IL-1α + TNF-α) (Figure 11).  
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Figure 9: Percent sGAG loss in cartilage explants increases with IL-1α and TNF-α 
and decreases with DEX treatments: Percent sGAG loss measured from immature 
bovine cartilage after a 6-day culture. Disks were treated with IL-1α at 1 ng/mL and 
TNF-α at 25 ng/mL with and without DEX at 100 nM. Each group had n = 6 explants. * 
vs untreated control (p < 0.0001), # vs 1 ng/mL (p < 0.0001). 
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Figure 10: DNA content of explants did not differ significantly between IL-1α, TNF-
α, and DEX treatments: This DNA is normalized to wet weight. This demonstrates that 
the DNA content is consistent across the groups. No statistical difference between groups 
were found. 
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Figure 11: sGAG biosynthesis normalized to wet weight decreases with IL-1α and 
TNF-α, and increases with DEX treatments: * vs untreated control (p < 0.0001), # vs 1 
ng/mL (p < 0.0001). 
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Figure 12: sGAG biosynthesis normalized to DNA content (shown in Figure 11) 
decreases with IL-1α, and TNF-α, and increases with DEX treatments: * vs untreated 
control (p < 0.0001), # vs 1 ng/mL (p < 0.0001). 
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Exogenous cytokines IL-1α and TNF-α decrease viability and DEX treatment 
improves viability 
 Control IL-1α + TNF-
α 
No DEX 
  
DEX  100 nM 
  
Figure 13: Cell viability worsens with IL-1α and TNF-α treatment and improves 
with DEX treatments: Viability was conducted on day 5. Images 1 and 2 are explants 
that did not receive DEX treatments and 3-6 received 100 nM of DEX. IL-1α was at a 
concentration of 1 ng/mL and TNF-α was at a concentration of 25 ng/mL. PI was used to 
stain dead cells red and FDA stained live cells green.  
The cell viability test demonstrated that the cells in the untreated condition were 
alive (Figure 13 image 1). Addition of IL-1α and TNF-α together led to a decrease in cell 
viability as indicated by the increase in red cells (Figure 13 compare 2 to 1). Addition of 
DEX alone did not alter cell viability (Figure 13 compare 1 to 3). DEX improved cell 
viability when in comparison with the group treated with both cytokines (Figure 13 
compare 4 to 2). 
1 2 
3 4 
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Addition of IL-1α and TNF-α lead to greater sGAG loss from the cartilage 
explants and a decreased biosynthesis rate. These cytokines also decrease cell viability. 
Addition of DEX decreases sGAG loss and increases sGAG biosynthesis rate when 
treating cartilage explants subjected to IL-1α but not IL-1α with TNF-α or TNF-α alone.   
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DISCUSSION 
 
The goal of this study was to examine the effects of inflammatory cytokines on 
sGAG biosynthesis in chondrocytes and to determine the effectiveness of an anti-
inflammatory drug dexamethasone on combating cartilage degradation. In OA, there is a 
decrease in matrix macromolecules synthesis and an increase in cartilage degradation 
(van den Berg et al., 1999). Cytokines IL-1α and TNF-α both are involved in the 
breakdown of cartilage tissue with IL-1 being more potent than TNF-α (van den Berg et 
al., 1999). We hypothesized that inflammatory cytokines IL-1α and TNF-α would 
increase sGAG loss from the cartilage explants and decrease sGAG biosynthesis since 
these cytokines promote cell catabolic pathways. In addition, we hypothesized that 
glucocorticoids such as DEX would ameliorate the catabolic effect on cartilage cells 
induced by IL-1α and TNF-α by improving sGAG biosynthesis and minimizing sGAG 
loss. We also hypothesized that glucocorticoids would improve cell viability of cytokine-
treated explants when compared with groups treated with cytokines alone.   
By treating cartilage explants harvested from a bovine knee joint with 
inflammatory cytokines IL-1α and TNF-α, the degradation of cartilage, similar to that 
seen in OA, was simulated. Li et al. studied IL-1α at 1 ng/mL (equivalent of moderate 
inflammation in a human joint) in explants harvest from human ankle and knee joints and 
found this cytokine treatment decreased sGAG biosynthesis and increased sGAG loss (Li 
et al., 2015). The experiments done in this study demonstrated that IL-1α and TNF-α 
together increase sGAG loss from the cartilage explants and decrease sGAG biosynthesis 
(Figure 4 and 7 and 9 and 12). IL-1α and TNF-α both decrease cell viability (Figure 8).  
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The experiments in this study showed that DEX treatment mitigated the effect of 
IL-1α by improving sGAG biosynthesis and decreasing sGAG loss in cartilage explants 
treated with IL-1α (Figure 4 and 7 and 9 and 12). However, DEX did not improve these 
conditions in explants treated with IL-1α and TNF-α together or TNF-α alone (Figure 9 
and 12). Lu et al. studied TNF-α (25 ng/mL) and DEX at several concentrations finding 
that DEX dose-dependently prevented sGAG loss and the DEX concentration that 
improved sGAG biosynthesis the most was 100 nM (Lu et al., 2011). Lu et al. then 
studied TNF-α together with IL-6 and sIL-6R together and found that 10 nM of DEX 
significantly reduced sGAG loss in cartilage explants subjected to these cytokines (Lu et 
al., 2011).  
 
Effects of IL-1 and TNF-α 
Collagen type II is a major component of the ECM and is encoded by the 
COL2A1 gene (Chadjichristos et al., 2003). In chondrocytes, addition of IL-1 decreases 
levels of aggrecan mRNA and as a result collagen type II levels also decrease (Robbins et 
al., 2001). IL-1 decreases collagen type II production by activating the NF-κB pathway to 
reduce transcription of COL2A1 (Goldring et al., 1988; Robbins et al., 2001). IL-1 also 
stimulates IL-6 and IL-8 production (Guerne et al., 1990; Lotz et al., 1992). IL-6 has a 
regulatory effect on inflammation and immune response and is found in synovial fluid 
extracted from arthritic joints (Guerne et al., 1990). TNF-α also increases production of 
IL-6 and IL-8 but not to the same extent as IL-1 (Guerne et al., 1990; Lotz et al., 1992).  
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Effects of DEX 
When studying differentiation of a clonal cell line RCJ 3.1, differentiation into 
adipocytes and chondrocytes only occurred when DEX had been added to the cell culture 
(Grigoridadis et al., 1988). Research by Maor et al. suggests DEX’s effect on cartilage 
tissue involves changing calcium metabolism in cartilage by increasing calcium influx 
into condylar tissue since addition of a calcium blocker eliminated DEX effects (Maor 
and Silbermann, 1986). Calcium is a regulator in proliferation and differentiation, is a 
second messenger in phosphorylation pathways, and activates enzymes such as 
phospholipase A all of which can lead to changes in transcription levels (Jensen et al., 
1990).   
 
Targeting IL-1 and TNF-α with DEX 
A main effect of the inflammatory cytokines present in OA is to decrease 
transcription and production of collagen type II. Because DEX also regulates 
transcription increasing DNA and protein synthesis, DEX is a promising treatment to 
increase the lost ECM macromolecules in joints with OA (Maor and Silbermann, 1986). 
DEX’s anti-catabolic effect can counteract the pro-catabolic effects of IL-1α (Lu et al., 
2011).  
 
Alternative treatments to DEX alone 
Li et al. studied DEX and IGF-1 together in explants from human knee and ankle 
joints to study how the treatments worked together. IGF-1 stimulates matrix biosynthesis 
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while DEX inhibits loss of matrix molecules (Tyler, 1989). These treatments together 
with an IL-1α concentration of 1 ng/mL was more effective than either treatment alone at 
preventing sGAG loss and promoting sGAG biosynthesis (Li et al., 2015).  
 
Other cytokines and combinations 
As mentioned previously, IL-6 is another inflammatory cytokine present in OA 
afflicted joints. This cytokine is found in the synovial fluid along with its soluble receptor 
sIL-6R (Lu et al., 2011). Lu et al. added TNF-α (25 ng/mL) and IL-6/sIL-6R (50/250 
ng/mL) together to cartilage explants. DEX treatment (10 nM) improved sGAG 
biosynthesis and decreased sGAG loss from bovine cartilage explants (Lu et al., 2011). 
Since in this study the effects of TNF-α and IL-1α were not ameliorated by DEX 
treatment, DEX dose should be investigated further in experiments with multiple 
cytokines present at once. In addition, since Li et al. noticed a stronger effect of IGF-1 
and DEX treatment together, experiments involving multiple cytokines should be tested 
with both treatments.  
 
Summary 
 Inflammatory cytokines lead to an increase in sGAG loss from cartilage tissue and 
decrease sGAG biosynthesis. DEX treatment improves the degrading effect of 
inflammatory cytokines in cartilage tissue by decreasing sGAG loss and increasing 
biosynthesis in cartilage.  
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